Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives.
Cell-based delivery
Delivery system
Hydrogel
Nanoparticle
Oncolytic virus
Virus delivery
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
14
02
2022
revised:
11
05
2022
accepted:
18
05
2022
pubmed:
28
5
2022
medline:
22
6
2022
entrez:
27
5
2022
Statut:
ppublish
Résumé
Oncolytic viruses (OVs) harness the hallmarks of tumor cells and cancer-related immune responses for the lysis of malignant cells, modulation of the tumor microenvironment, and exertion of vaccine-like activities. However, efficient clinical exploitation of these potent therapeutic modules requires their systematic administration, especially against metastatic and solid tumors. Therefore, developing methods for shielding a virus from the neutralizing environment of the bloodstream while departing toward tumor sites is a must. This paper reports the latest advancements in the employment of chemical and biological compounds aimed at safe and efficient delivery of OVs to target tissues or tumor deposits within the host.
Identifiants
pubmed: 35623296
pii: S1567-5769(22)00366-6
doi: 10.1016/j.intimp.2022.108882
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
108882Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.